Capital One Financial Equities Analysts Boost Earnings Estimates for Fennec Pharmaceuticals Inc. (TSE:FRX)

Fennec Pharmaceuticals Inc. (TSE:FRX) – Capital One Financial boosted their FY2025 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a report issued on Thursday, May 2nd. Capital One Financial analyst N. Quibria now expects that the biopharmaceutical company will post earnings per share of $0.97 for the year, up from their prior estimate of $0.96. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.42 per share. Capital One Financial also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $1.63 EPS and FY2028 earnings at $4.63 EPS.

Fennec Pharmaceuticals (TSE:FRX) last announced its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported C($0.14) EPS for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a negative net margin of 75.50%. The company had revenue of C$13.25 million for the quarter, compared to analysts’ expectations of C$12.88 million.

Fennec Pharmaceuticals Stock Performance

Shares of Fennec Pharmaceuticals stock opened at C$12.58 on Monday. Fennec Pharmaceuticals has a one year low of C$9.27 and a one year high of C$15.43. The company has a market cap of C$340.92 million, a price-to-earnings ratio of -15.34 and a beta of 0.40. The company has a debt-to-equity ratio of 881.09, a quick ratio of 10.17 and a current ratio of 3.56. The business’s 50 day moving average price is C$13.56 and its 200 day moving average price is C$12.92.

Insider Buying and Selling

In other Fennec Pharmaceuticals news, Senior Officer Adrian J. Haigh bought 22,222 shares of Fennec Pharmaceuticals stock in a transaction on Monday, April 15th. The shares were bought at an average price of C$2.31 per share, for a total transaction of C$51,332.82. In other Fennec Pharmaceuticals news, Senior Officer Robert Christopher Andrade sold 13,975 shares of Fennec Pharmaceuticals stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of C$10.90, for a total value of C$152,345.67. Also, Senior Officer Adrian J. Haigh bought 22,222 shares of Fennec Pharmaceuticals stock in a transaction on Monday, April 15th. The stock was acquired at an average price of C$2.31 per share, for a total transaction of C$51,332.82. Over the last 90 days, insiders have sold 39,112 shares of company stock worth $390,926. 14.60% of the stock is owned by corporate insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.